西班牙人群中SLEDAI与SLE-DAS强相关:不一致患者评估
该回顾性研究纳入西班牙马德里Fundación Jiménez Díaz医院2010至2024年随访的324例系统性红斑狼疮患者,采用SLEDAI-2K与SLE-DAS评估疾病活动度。两工具呈强相关(ρ=0.970,p<0.001)和高一致性(线性加权Kappa指数=0.7715,p<0.001),44例分类不一致,其中37例SLE-DAS分类的活动度高于SLEDAI-2K。
要点
- SLEDAI-2K与SLE-DAS强相关(ρ=0.970,p<0.001),线性加权Kappa指数=0.7715(p<0.001)。
- 44例活动度分类不一致,其中39例仅相差一个等级,37例SLE-DAS分类高于SLEDAI-2K。
- 皮肤和血液学表现的患者更常见活动度分类不一致。
核心结论
- SLEDAI-2K与SLE-DAS在西班牙人群中评估疾病活动度呈强相关和高可重复性。
- SLE-DAS提供额外信息,尤其在血液学和皮肤受累患者中,能更精确评估SLE疾病活动度。
研究设计与样本
- 回顾性评估西班牙马德里Fundación Jiménez Díaz医院2010至2024年随访的324例SLE患者。
- 数据取自患者最近一次访视,使用SLEDAI-2K和SLE-DAS评估疾病活动度,并分析两工具分类不一致情况。
主要发现
- 缓解:临床SLEDAI-2K=0为254例(78.4%),临床SLE-DAS=0(不考虑血清学,泼尼松≤5 mg/天)为253例(78.3%)。
- 低活动度:SLEDAI-2K 1-4且泼尼松≤5 mg/天为42例(13.0%),SLE-DAS>0且≤2.48且泼尼松≤7.5 mg/天为14例(4.3%)。
- 轻度活动:SLEDAI-2K 1-4且泼尼松>5 mg/天或评分5-6为19例(5.9%),SLE-DAS>0且≤2.48且泼尼松>7.5 mg/天或评分>2.48且≤7.64为46例(14.2%)。
- 中度活动:SLEDAI-2K 7-12为7例(2.2%),SLE-DAS>7.64且≤9.9为3例(0.9%)。
- 重度活动:SLEDAI-2K>12为2例(0.6%),SLE-DAS>9.9为7例(2.2%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Assessing disease activity in systemic lupus erythematosus (SLE) is essential for effective treatment. SLEDAI-2 K uses dichotomous items, while SLE-DAS incorporates both dichotomous and continuous variables, OBJECTIVES: To analyze the correlation between SLEDAI-2 K and SLE-DAS in SLE patients from central Spain and analyze factors leading to discordance in disease activity classification. METHODS: Retrospective assessment of 324 SLE patients followed up from 2010 to 2024 at Madrid's Fundación Jiménez Díaz Hospital (Spain). Data were collected from the patients' most recent visits and disease activity was evaluated using SLEDAI-2 K and SLE-DAS, and discordant classifications between the tools were analyzed. RESULTS: The number of patients in each disease activity category was as follows: Remission (Clinical SLEDAI-2 K = 0, n = 254 [78.4 %] vs. clinical SLE-DAS =0, regardless of serology, and prednisone up to 5 mg/day, n = 253 [78.3 %]); Low activity (SLEDAI-2 K 1-4 and prednisone dose ≤ 5 mg/day, n = 42 [13.0 %] vs. SLE-DAS >0 and ≤ 2.48 with prednisone dose ≤ 7.5 mg/day, n = 14 [4.3 %]); Mild activity (SLEDAI-2 K 1-4 and prednisone dose > 5 mg/day or score 5-6, n = 19 [5.9 %] vs. SLE-DAS >0 and ≤ 2.48 with prednisone dose > 7.5 mg/day or score >2.48 and ≤7.64, n = 46 [14.2 %]); Moderate (SLEDAI-2 K 7-12 n = 7 [2.2 %] vs. SLE-DAS >7.64 and ≤9.9,n = 3 [0.9 %]); Severe SLEDAI-2 K > 12 (n = 2 [0.6 %] vs. SLE-DAS >9.9,n = 7 [2.2 %]). SLEDAI-2 K and SLE-DAS showed strong correlation (ρ=0.970, p < 0.001), with high concordance (linearly weighted Kappa index=0.7715, p < 0.001). Forty-four patients were discordant in terms of disease activity categorization. Of these, 39 were discordant at only one level of disease activity. Notably, in 37 of the 44 cases, SLE-DAS classified patients as having a higher degree of disease activity compared to SLEDAI-2 K. Patients with skin and hematological manifestations were more commonly discordant in terms of disease activity. CONCLUSION: SLEDAI-2 K and SLE-DAS demonstrate a strong correlation and high reproducibility for assessing disease activity in the Spanish population. However, SLE-DAS offers additional information, particularly in patients with hematologic and skin involvement, enabling a more precise evaluation of disease activity in SLE patients.
引用
- Heras-Recuero E, García-Fernández A, Blázquez-Sánchez T, et al. Strong correlation between SLEDAI and SLE-DAS in the Spanish population: Assessment of discordant patients. Semin Arthritis Rheum. 2025. PMID: 40403526. doi:10.1016/j.semarthrit.2025.152758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。